AG-236 / Alnylam, Agios Pharma - LARVOL DELTA

Key Upcoming Milestones & Priorities (GlobeNewswire) - "LR-MDS: Complete patient enrollment in the Phase 2b study of tebapivat for LR-MDS in late 2025; Early-Stage Pipeline: File an Investigational New Drug Application for AG-236, an siRNA targeting TMPRSS6 intended for the treatment of polycythemia vera, in mid-2025."

Enrollment status • IND • Myeloproliferative Neoplasm • Polycythemia Vera

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire) - "'Backed by a strong balance sheet and a highly experienced team, Agios is focused on maximizing the potential PYRUKYND launches in thalassemia and sickle cell disease in 2025 and 2026, respectively'...PYRUKYND Revenues: Generated $10.7 million in net revenue for the fourth quarter of 2024, a 20 percent increase from the third quarter of 2024, primarily driven by year-end stocking and adjustments to certain revenue reserves...Announce topline results from the Phase 3 RISE UP study of mitapivat in sickle cell disease in late 2025...Additionally, begin patient enrollment for the Phase 2 study of tebapivat in sickle cell disease in mid-2025. LR-MDS: Complete patient enrollment in the Phase 2b study of tebapivat for LR-MDS in late 2025. Early-Stage Pipeline: File an Investigational New Drug Application for AG-236, a siRNA targeting TMPRSS6 intended for the treatment of polycythemia vera, in mid-2025."

Commercial • Enrollment status • IND • Launch US • P3 data: top line • Anemia • Beta-Thalassemia • Hematological Disorders • Myelodysplastic Syndrome • Polycythemia Vera • Sickle Cell Disease

Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio (GlobeNewswire) - "Anticipated 2025 Milestones: Lower-Risk Myelodysplastic Syndromes (LR-MDS): Complete patient enrollment in the Phase 2b study of tebapivat for LR-MDS in late 2025. Early-Stage Pipeline: File an Investigational New Drug Application for AG-236, a siRNA targeting TMPRSS6 intended for the treatment of polycythemia vera, in mid-2025."

Enrollment status • IND • Myelodysplastic Syndrome • Polycythemia Vera

Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia Vera (GlobeNewswire) - "Agios Pharmaceuticals, Inc...has entered into an exclusive worldwide license agreement with Alnylam Pharmaceuticals, Inc. under which Agios will acquire the rights to develop and commercialize Alnylam’s novel preclinical siRNA targeting TMPRSS6, as a potential disease-modifying treatment for patients with polycythemia vera (PV)....Under the terms of the agreement, Agios will make an upfront payment of $17.5 million to Alnylam for an exclusive global license to the TMPRSS6 siRNA program. In addition, Alnylam is eligible to receive up to $130 million in potential development and regulatory milestone payments, in addition to sales milestones and tiered royalties. Agios will assume sole responsibility for all development, regulatory, and commercial activities and costs related to the program. Alnylam will provide manufacturing support for Phase 1, after which Agios will assume full responsibility for manufacturing."

Licensing / partnership • Hematological Malignancies • Myeloproliferative Neoplasm • Oncology • Polycythemia Vera